Human IgE-independent systemic anaphylaxis - 03/06/16
, Marat V. Khodoun, PhD a, b, Richard Strait, MD d, eAbstract |
Anaphylaxis is a rapidly developing, life-threatening, generalized or systemic allergic reaction that is classically elicited by antigen crosslinking of antigen-specific IgE bound to the high-affinity IgE receptor FcεRI on mast cells and basophils. This initiates signals that induce cellular degranulation with release and secretion of vasoactive mediators, enzymes, and cytokines. However, IgE-independent mechanisms of anaphylaxis have been clearly demonstrated in experimental animals. These include IgG-dependent anaphylaxis, which involves the triggering of mediator release by IgG/antigen complex crosslinking of FcγRs on macrophages, basophils, and neutrophils; anaphylaxis mediated by binding of the complement-derived peptides C3a and C5a to their receptors on mast cells, basophils, and other myeloid cells; and direct activation of mast cells by drugs that interact with receptors on these cells. Here we review the mechanisms involved in these IgE-independent forms of anaphylaxis and the clinical evidence for their human relevance. We conclude that this evidence supports the existence of all 3 IgE-independent mechanisms as important causes of human disease, although practical and ethical considerations preclude their demonstration to the degree of certainty possible with animal models. Furthermore, we cite evidence that different clinical situations can suggest different mechanisms as having a primal role in anaphylaxis and that IgE-dependent and distinct IgE-independent mechanisms can act together to increase anaphylaxis severity. As specific agents become available that can interfere with mechanisms involved in the different types of anaphylaxis, recognition of specific types of anaphylaxis is likely to become important for optimal prophylaxis and therapy.
Le texte complet de cet article est disponible en PDF.Key words : Anaphylatoxin, complement, FcεR, FcγR, IgE, IgG, mast cell, basophil, mouse
Abbreviations used : NSAID, PAF, TNP
Plan
| Some of the work mentioned in this article has been supported by the National Institutes of Health (R01AI113162 and R21AI103816), a Merit Award from the US Department of Veterans Affairs, the US Department of Defense (PR120718), and Food Allergy Research and Education. |
|
| Disclosure of potential conflict of interest: F. D. Finkelman receives research funding from the National Institute of Health, Veteran's Administration, and Department of Defense. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 137 - N° 6
P. 1674-1680 - juin 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
